Mayne Pharma launches generic Clozaril
GREENVILLE, N.C. — Mayne Pharma’s newest portfolio addition is its generic of Clorazil (clozapine) tablets. The antipsychotic is indicated to treat severely ill patients with schizophrenia and to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.
“The launch of the full range of Clozapine tablets is our sixth product launch in 2017 and will further diversify our product offering,” Mayne Pharma CEO Scott Richards said.
Richards noted that the Clozaril generic — currently supplied by Teva — would ultimately be manufactured at Mayne Pharma’s Greenville, N.C. facility that is set to open in early 2018. The solid oral dose facility is set to quadruple the company’s U.S. manufacturing capacity, Richards said.
The company’s Clozaril generic will be available in 25-, 50-, 100- and 200-mg dosage strengths. The treatment had U.S. sales of roughly $130 million for the 12 months ended July 31, according to QuintilesIMS data. The drug was approved under a Risk Evaluation and Management Strategy called the Clozapine REMS Program.